Catalyst Pharmaceutical

settlement
Pharma

Catalyst's Teva settlement postpones arrival of Firdapse generic

Thanks to a new settlement with Catalyst, Teva is barred from marketing its Firdapse generic in the U.S. until Feb. 25, 2035, at the earliest.
Fraiser Kansteiner Jan 9, 2025 10:08am
Eisai new US headquarters

Eisai peddles US rights to epilepsy drug Fycompa to Catalyst

Dec 20, 2022 10:35am